LIN vs VMD
LIN: A global leader in industrial gases and engineering solutions supporting critical processes across virtually every sector of the economy. VMD: Viemed is a specialized provider of home-based respiratory care and chronic disease management that aims to lower healthcare costs by treating patients in their homes.
Side-by-side fundamentals
| Metric | LIN | VMD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $481.70 | $9.41 | |
| Market cap | $222.1B | $358M | |
| P/E as of 2026-10-08 | 31.10 | 26.25 | VMD lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 1.47 | 0.81 | VMD lower |
| Net margin FY2025, SEC XBRL | +20.3% | +5.5% | LIN higher |
| Gross margin FY2025, SEC XBRL | n/a | +57.5% | |
| Operating margin FY2025, SEC XBRL | +26.3% | +8.5% | LIN higher |
| ROE FY2025, SEC XBRL | +17.4% | +10.6% | LIN higher |
| ROA FY2025, SEC XBRL | +7.9% | +7.5% | LIN higher |
| Debt / equity as of 2026-09-03 | 0.72 | 0.05 | VMD lower |
| Revenue growth (YoY) as of 2026-09-03 | +6.6% | +25.2% | VMD higher |
| Revenue CAGR (3y) SEC XBRL | +0.6% | +24.9% | VMD higher |
| Dividend yield as of 2026-09-03 | +1.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 10 | 0 | LIN higher |
| Beta as of 2026-09-03 | 0.45 | 0.39 | |
| 1-year return as of 2026-10-08 close | +3.0% | +37.0% | VMD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.